Reuters reports:
Pfizer Inc has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anti-competitive and unfair practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan.
The proposed class action settlement was disclosed in a filing in federal court in Kansas City, Kansas. The deal, which requires a judge’s approval, would not resolve claims against Mylan, which is scheduled to face trial in January.
Paul Geller, a lawyer for the plaintiffs, said they were “pleased that Pfizer resolved its part of this class action lawsuit over the pricing of EpiPens.”
Read the full article.
Pfizer Inc (PFE.N) has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anticompetitive and unfair practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan. https://t.co/nhJesWnthg
— Reuters Health (@Reuters_Health) July 16, 2021